Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Malignant Melanoma.
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Jun 2009 Planned number of patients changed from 20 to 40 as reported by ClinicalTrials.gov.
- 02 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.